ISG15 as a Prognostic Marker in Breast Cancer
Author Information
Author(s): Bektas Nuran, Noetzel Erik, Veeck Jürgen, Press Michael F, Kristiansen Glen, Naami Amjad, Hartmann Arndt, Dimmler Arno, Beckmann Matthias W, Knüchel Ruth, Fasching Peter A, Dahl Edgar
Primary Institution: University Hospital of the RWTH Aachen
Hypothesis
ISG15 expression levels correlate with prognosis in breast cancer patients.
Conclusion
ISG15 may serve as a novel prognostic marker in breast cancer, indicating a potential for predicting treatment response.
Supporting Evidence
- ISG15 was overexpressed in breast carcinoma cells compared to normal breast tissue.
- Significant correlation between ISG15 overexpression and unfavourable prognosis was found.
- Patients with high ISG15 expression had a mean recurrence-free survival of 112 months.
Takeaway
ISG15 is a molecule that can help doctors understand how serious a breast cancer might be, and it might help them choose the right treatment.
Methodology
The study used real-time PCR, cDNA dot-blot hybridization, and immunohistochemistry to analyze ISG15 expression in breast cancer and normal tissues.
Limitations
The study may not account for all variables affecting ISG15 expression and its prognostic value.
Participant Demographics
Patients aged 25 to 82 years, median age 56 years.
Statistical Information
P-Value
p = 0.001
Confidence Interval
95% CI: 99 to 125
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website